Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,095 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis.
Bracarda S, Iacovelli R, Boni L, Rizzo M, Derosa L, Rossi M, Galli L, Procopio G, Sisani M, Longo F, Santoni M, Morelli F, Di Lorenzo G, Altavilla A, Porta C, Camerini A, Escudier B; Rainbow Group. Bracarda S, et al. Among authors: longo f. Ann Oncol. 2015 Oct;26(10):2107-13. doi: 10.1093/annonc/mdv315. Epub 2015 Jul 27. Ann Oncol. 2015. PMID: 26216384 Free article.
Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis.
Bracarda S, Iacovelli R, Boni L, Rizzo M, Derosa L, Rossi M, Galli L, Procopio G, Sisani M, Longo F, Santoni M, Morelli F, Di Lorenzo G, Altavilla A, Porta C, Camerini A, Escudier B; Rainbow Group. Bracarda S, et al. Among authors: longo f. Ann Oncol. 2016 Feb;27(2):366. doi: 10.1093/annonc/mdv589. Epub 2015 Dec 18. Ann Oncol. 2016. PMID: 26685011 Free article. No abstract available.
Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial.
Rulli E, Marabese M, Torri V, Farina G, Veronese S, Bettini A, Longo F, Moscetti L, Ganzinelli M, Lauricella C, Copreni E, Labianca R, Martelli O, Marsoni S, Broggini M, Garassino MC; TAILOR trialists. Rulli E, et al. Among authors: longo f. Ann Oncol. 2015 Oct;26(10):2079-84. doi: 10.1093/annonc/mdv318. Epub 2015 Jul 24. Ann Oncol. 2015. PMID: 26209642 Free article. Clinical Trial.
[Renal carcinoma update and prospectives].
Longo F, Mansueto G. Longo F, et al. Tumori. 2008 Jan-Feb;94(1):suppl 1-9. Tumori. 2008. PMID: 18472437 Italian. No abstract available.
Epigenetic control of gene expression: Potential implications for cancer treatment.
Perri F, Longo F, Giuliano M, Sabbatino F, Favia G, Ionna F, Addeo R, Della Vittoria Scarpati G, Di Lorenzo G, Pisconti S. Perri F, et al. Among authors: longo f. Crit Rev Oncol Hematol. 2017 Mar;111:166-172. doi: 10.1016/j.critrevonc.2017.01.020. Epub 2017 Feb 4. Crit Rev Oncol Hematol. 2017. PMID: 28259291 Review.
Palonosetron plus 3-day aprepitant and dexamethasone to prevent nausea and vomiting in patients receiving highly emetogenic chemotherapy.
Longo F, Mansueto G, Lapadula V, De Sanctis R, Quadrini S, Grande R, Gori B, Altavilla A, D'Antoni I, Del Signore E, Stumbo L, De Luca C, Cimadon B, Cortesi E, Gamucci T, Di Seri M. Longo F, et al. Support Care Cancer. 2011 Aug;19(8):1159-64. doi: 10.1007/s00520-010-0930-x. Epub 2010 Jun 16. Support Care Cancer. 2011. PMID: 20552375
1,095 results